Luis E Raez, Chief Scientific Officer and Medical Director of Memorial Healthcare System, shared on LinkedIn:
“Memorial Cancer Institute at Memorial Healthcare System was one of the first US cancer centers to enroll patients with this new bispecific for lung cancer, the results were presented orally last week as late abstract at STIC 2026 in patients that have developed already resistance to immunotherapy.
Thanks to ONC4 for the collaboration!”
You can also read: Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR.
